The news. The narrative. The timeline.
Bureau: Chicago
NICE closed its lecanemab and donanemab consultation Tuesday with the new Cochrane review filed; the appraisal committee meets June 10 and the math is now post-threshold-revision.
Friday is the first MMWR cycle under Sara Brenner's principal-deputy line, and the queue holds the operational hep-B birth-dose guidance the agency walked back in December.
A Hopkins study of 175,000 type 1 diabetes patients put GLP-1s' five-year cardiovascular and kidney-disease risk reductions at 15 and 19 percent.
An FDA radiologist who advocated faster device review now sits at the editorial gate of the agency that publishes American disease data.